{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:55:01Z","timestamp":1774896901222,"version":"3.50.1"},"reference-count":20,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Alemtuzumab has been associated with the emergence of secondary autoimmune diseases. We report a case of a patient with relapsing\u2013remitting multiple sclerosis who developed a refractory immune thrombocytopaenia associated with vasculitis, myelofibrosis and later Guillain-Barr\u00e9 syndrome following alemtuzumab. The medical community should be aware of unusual and unexpected adverse events that may be associated with alemtuzumab, especially when occurring simultaneously in the same patient.<\/jats:p>","DOI":"10.1136\/bcr-2021-248037","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T13:31:15Z","timestamp":1656336675000},"page":"e248037","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Autoimmune storm following alemtuzumab"],"prefix":"10.1136","volume":"15","author":[{"given":"Chelsea","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beauchemin","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Neurologie, Faculte de medecine - Universite Laval, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Luiza","family":"Sayao","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mollie","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Rheumatology, Arthritis Research Canada, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"2025082710553732000_15.6.e248037.1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww258"},{"key":"2025082710553732000_15.6.e248037.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"2025082710553732000_15.6.e248037.3","unstructured":"Coles A . Detection and management of immune thrombocytopenia in alemtuzumab treated patients in the multiple sclerosis clinical development program. In: ECTRIMS. Barcelona, 2015."},{"key":"2025082710553732000_15.6.e248037.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827b5927"},{"key":"2025082710553732000_15.6.e248037.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228bec5"},{"key":"2025082710553732000_15.6.e248037.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"2025082710553732000_15.6.e248037.7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s13760-017-0799-2","article-title":"Atypical acute motor axonal neuropathy following alemtuzumab treatment in multiple sclerosis patient","volume":"117","author":"Hradilek","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"2025082710553732000_15.6.e248037.8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517694431"},{"key":"2025082710553732000_15.6.e248037.9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/1352458516688350","article-title":"Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab","volume":"23","author":"Clerico","year":"2017","journal-title":"Mult Scler"},{"key":"2025082710553732000_15.6.e248037.10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","article-title":"Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis","volume":"43","author":"Scappaticcio","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"2025082710553732000_15.6.e248037.11","article-title":"Idiopathic thrombocytopenic purpura: a rare syndrome with alemtuzumab, review of monitoring protocol","volume":"11","author":"Sarvepalli","year":"2019","journal-title":"Cureus"},{"key":"2025082710553732000_15.6.e248037.12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1177\/1352458519895449","article-title":"ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis","volume":"26","author":"Horisberger","year":"2020","journal-title":"Mult Scler"},{"key":"2025082710553732000_15.6.e248037.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102141","article-title":"Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: a case report","volume":"41","author":"Alnahdi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025082710553732000_15.6.e248037.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371138"},{"key":"2025082710553732000_15.6.e248037.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-291831"},{"key":"2025082710553732000_15.6.e248037.16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000479103","article-title":"Autoimmune myelofibrosis: clinical features, course, and outcome","volume":"138","author":"Piatek","year":"2017","journal-title":"Acta Haematol"},{"key":"2025082710553732000_15.6.e248037.17","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516638558"},{"key":"2025082710553732000_15.6.e248037.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307721"},{"key":"2025082710553732000_15.6.e248037.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565"},{"key":"2025082710553732000_15.6.e248037.20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/imm.12696","article-title":"Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis","volume":"150","author":"von Kutzleben","year":"2017","journal-title":"Immunology"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-248037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:55:57Z","timestamp":1756317357000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-248037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,27]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bcr-2021-248037"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-248037","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}